Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

COSCIENS Biopharma (0UGB) Share Price & Analysis

0 Followers

0UGB Stock Chart & Stats

CA$8.51CA$0.00(0.00%)
At close: 4:30 PM GMT
C$7.5C$8C$8.5Sep 14Oct 30
Day’s Range
CAD 8.51 - CAD 8.51
52-Week Range
CAD 7.45 - CAD 12.74
Previous Close
CAD 8.51
Volume
N/A
Average Volume (3M)
3
Market Cap
CAD 8.37M
Enterprise Value
CAD 1.56M
Total Cash (Recent Filing)
CAD 5.27M
Total Debt (Recent Filing)
CAD 1.95M
Price to Earnings (P/E)
―
Beta
-0.10
Next Earnings
Nov 17, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Gross Margin

The substantial gross-margin improvement indicates better economics on existing revenue and may provide a foundation for future operating leverage. If maintained, stronger product-level profitability can help COSCIENS fund development more efficiently and reduce the scale of losses over coming quarters.

Narrowing Net Losses

Materially narrowing losses show that the company is moving in the right direction operationally, even though it has not reached profitability. Continued improvement would extend its financial runway, reduce the burden on future funding, and improve the potential for operating leverage as revenue develops.

Conservative Leverage

A relatively modest debt burden gives COSCIENS greater flexibility than a highly levered balance sheet would provide. Lower financial leverage limits interest and refinancing pressure, allowing management to direct more resources toward therapeutic development while retaining capacity to respond to business volatility.

Bears Say

Persistent Unprofitability

Deeply negative margins and returns show that the current business model is not yet generating adequate economic returns for shareholders. Until revenue scales or expenses decline substantially, continued losses can constrain reinvestment, weaken equity returns, and make durable profitability uncertain.

Continued Cash Burn

Negative operating and free cash flow means COSCIENS is not currently self-funding its activities, despite the improvement from earlier periods. Persistent cash consumption can increase dependence on external financing and may limit the pace of product development if operating performance does not improve.

Limited Revenue Momentum

The modest TTM revenue increase suggests stabilization rather than strong commercial expansion, following a prior decline. Limited top-line momentum makes it harder to absorb the company’s fixed development and operating costs, delaying the scale benefits needed to convert improving gross margins into profitability.

COSCIENS Biopharma News

0UGB FAQ

What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest share price was C$7.45 and its highest was C$12.74 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$8.37M.
When is COSCIENS Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -C$0.267 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.267 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in GB:0UGB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology